Compare TXMD & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TXMD | NEUP |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9M | 21.7M |
| IPO Year | N/A | N/A |
| Metric | TXMD | NEUP |
|---|---|---|
| Price | $2.49 | $4.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | ★ 121.4K | 33.0K |
| Earning Date | 03-26-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | $2,796,000.00 | ★ $15,649,448.00 |
| Revenue This Year | $427.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $91.22 | ★ N/A |
| Revenue Growth | ★ 75.19 | N/A |
| 52 Week Low | $0.72 | $3.65 |
| 52 Week High | $2.95 | $21.40 |
| Indicator | TXMD | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 56.50 | 44.49 |
| Support Level | $2.12 | $3.98 |
| Resistance Level | $2.54 | $4.11 |
| Average True Range (ATR) | 0.27 | 0.12 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 36.78 | 10.34 |
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.